Sector Expert: Simos Simeonidis

Cowen & Co.



Recent Quotes

"Given CYTR's valuation, we view the current risk/reward as favorable."

— Simos Simeonidis, Cowen & Co. (5/10/13)
more >

"We rate CYTR Outperform."

— Simos Simeonidis, Cowen & Co. (3/11/13)
more >

"Aldoxorubicin continues to be the most promising compound in CYTR's pipeline."

— Simos Simeonidis, Cowen & Co. (11/9/12)
more >

"We are initiating coverage of IMUC."

— Simos Simeonidis, Cowen & Co. (2/17/12)
more >



Due to permission requirements, not all quotes are shown.